Search results
For 175 years, Pfizer has been a trusted partner in healthcare – discovering, developing, and delivering medical breakthroughs to prevent, treat, and cure some of the world’s most vexing conditions and diseases. Learn more about our history.
Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
Dec 11, 2020 · COMIRNATY is the first COVID-19 vaccine to be granted FDA approval. Approval is based on a comprehensive submission package including six-month efficacy and safety data after second dose. More than 1.2 billion Pfizer-BioNTech doses have been delivered to more than 120 countries or territories around the world since December 2020.
Pfizer is a leading developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
Feb 29, 2024 · A Guide to our New Product Pipeline Visualization. We're elevating our breakthroughs in a bold new way on Pfizer.com. Check out our new visualized product pipeline, where you'll be able to take a deep dive into our working innovations and see where each product is in development! Find out more.
Pfizer Helpful Answers®, the pharmaceutical industry's most comprehensive prescription medicines access initiative is launched, enabling America's 45 million uninsured to obtain Pfizer medicines free or at significant savings.
Pfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose ...
Aug 23, 2021 · FDA approved the first COVID-19 vaccine, which has been known as the Pfizer-BioNTech COVID-19 Vaccine, and is now marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease...
Sep 22, 2021 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age and older.
Jun 25, 2022 · Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron Geometric mean ratios for Omicron neutralizing antibody response ...
